 Oligopeptides
"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
| Descriptor ID |
D009842
|
| MeSH Number(s) |
D12.644.456
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 1 | 3 | 4 | | 1985 | 1 | 1 | 2 | | 1986 | 1 | 1 | 2 | | 1989 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 2 | 0 | 2 | | 1992 | 3 | 0 | 3 | | 1993 | 0 | 2 | 2 | | 1994 | 1 | 2 | 3 | | 1995 | 3 | 0 | 3 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 3 | 4 | | 1999 | 3 | 2 | 5 | | 2000 | 0 | 4 | 4 | | 2001 | 2 | 2 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 4 | 5 | | 2005 | 4 | 1 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 5 | 1 | 6 | | 2008 | 1 | 2 | 3 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 5 | 2 | 7 | | 2012 | 5 | 7 | 12 | | 2013 | 3 | 5 | 8 | | 2014 | 7 | 2 | 9 | | 2015 | 2 | 1 | 3 | | 2016 | 2 | 4 | 6 | | 2017 | 5 | 3 | 8 | | 2018 | 2 | 1 | 3 | | 2019 | 4 | 3 | 7 | | 2020 | 0 | 4 | 4 | | 2021 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 01; 23(1):65-76.
-
Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 10 12; 5(19):3748-3759.
-
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.
-
Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schecter JM, Chari A. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):701-710.
-
Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJ. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
-
Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020 12; 21(12):e540.
-
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
-
Deak P, Kimani F, Cassaidy B, Esser-Kahn A. Determining Whether Agonist Density or Agonist Number Is More Important for Immune Activation via Micoparticle Based Assay. Front Immunol. 2020; 11:642.
-
Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Bladé J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 04; 37(4):1464-1478.
-
He YJ, Santana MF, Moucka M, Quirk J, Shuaibi A, Pimentel MB, Grossman S, Rashid MM, Cinar A, Georgiadis JG, Vaicik MK, Kawaji K, Venerus DC, Papavasiliou G. Immobilized RGD concentration and proteolytic degradation synergistically enhance vascular sprouting within hydrogel scaffolds of varying modulus. J Biomater Sci Polym Ed. 2020 02; 31(3):324-349.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|